Skip to content

Lung Cancer Screening Implementation Among Employees at Lyon Hospital

Pilot Study on Lung Cancer Screening Implementation Among Employees at Lyon Hospital

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05452200
Acronym
ILYAD
Enrollment
600
Registered
2022-07-11
Start date
2022-09-21
Completion date
2024-09-12
Last updated
2023-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

lung cancer, screening, tobacco cessation, COPD

Brief summary

Several randomized studies have demonstrated the efficiency of lung cancer screening (LCS) on mortality rates. However, screening efficiency is related to the targeted population and the participation rate. In France, the participation rate for breast and colon cancer screening programs is respectively 50% and 32%, which is low. Then, it appears very important to determine which factors are influencing the willingness to participate to these programs. Indeed, it will allow a better communication and we will be able to perform screening campaigns adapted to the eligible population. The Lyon Hospital is the second university hospital in France. It is composed of 14 buildings and employed 23 000 persons. More than 160 occupations are represented. So, hospital employees look relevant to be studied for LCS program. ILYAD was divided in 2 parts. The first one was completed in 2020 and goal to evaluate the number of eligible individuals among the hospital employees. About 800 persons would be eligible for LCS. This second part of the study will evaluate the participation rate and the feasibility of the LCS program. The study will target the 800 individuals that were identified previously.

Interventions

BEHAVIORALSolicitation for lung cancer screening

3 levels of solicitation will be cumulated. First : a Simple collective solicitation of all staff via internal media 4 months later : Personalized indirect solicitation of at-risk groups with information posted in identified areas 4 months later : Personalized direct solicitation of at-risk groups

OTHERadded exams to the usual lung cancer screening

* spirometry examination * Questionnaires * Blood samples and breath samples to find biomarkers

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Inclusion Criteria : * Participant have to meet the criteria below: Lyon hospital employee at the day of inclusion: * valid hospital employee number, * Or retired employee for less than a year before the inclusion AND meeting eligibility criteria as follow : * Aged from 50 to 75 yo, * AND smoke or have smoked ≥ 10 cigarettes/day during ≥ 30 years OR ≥ 15 cigarettes/day for at least 25 years; * AND active smoker or smoking cessation for ≤ 15 years ; * Volunteer to start a program of smoking cessation if active smoker; * Consent form signed ; * Cover by health insurance. *

Exclusion criteria

: Participant have to NOT meet the criteria below : * Individual not working at Lyon hospital; * Individual not payed by the Lyon Hospital but working at it; * Individuals not willing to participate; * Individual working at René Sabran Hospital; * Individual meeting one of this non eligibility for LCS criteria defined by the French recommendation: * Not able to climb 2 floors of stairs ; * Weight ≥ 140Kg * Underwent a chest CT scan less than 1 year ago (except screening scanner); * History of lung cancer of less than 5 years or under treatment ; history of any cancer under monitoring by chest scanner ; * Comorbidity contraindicating therapeutic options or any kind of invasive interventions ; * Ongoing or recent respiratory symptoms that might lead to lung cancer diagnosis (hemoptysia, weight loss, recurrent respiratory infection). * Individual who is pregnant or breast feeding; * Individual whose mental health is not good enough to participate; * Individual in jail or under justice evaluation.

Design outcomes

Primary

MeasureTime frameDescription
Participation rate at baselineAt the baseline visitRatio between the number of participants who underwent a CT scan at baseline and the estimated number of eligible employees

Secondary

MeasureTime frameDescription
Identification of predictive factors for participation decisionAt baseline and At 1Year follow-upUsing the cox model to identify sociodemographic factors that could be associated with the participation rates for both round of CT scan.
Evaluation of feasibility of the LCS program by measuring the proportion of individuals having undergo all the required exams and evaluations according to the results of the CT scan, conformity of the scan interpretation, and adverse event monitoring.At baseline and At 1Year follow-upRatio between individuals who completed baseline and year 1 CT scan and the number of participants. And, the ratio of individuals who beneficiated conform care according to French recommendations.
Evaluation of screening efficiency according to the proportion of lung cancer, ILD, COPD diagnosed and the percentage of smoking cessation among the active smokers.At baseline and At 1Year follow-upRatio of lung cancer diagnosed Ration of ILD diagnosed Ratio of COPD diagnosed Ratio of smoking cessation
Participation rate according to the 3 communication levels.At 4 month = level 1 ; At 8 month = level 2 ; At 12 month = level 3Ratio between the number of participants who underwent the baseline CT scan at level 1, 2 and 3 and the estimated number of eligible employees
Identification of efficient biomarker for LC screeningAt baselinePerform blood analysis to identify specific biomarkers and compare their sensibility, and predictive value with or without association with the CT scan.
Evaluation of the efficiency of VOC for LC screeningAt baselinePerform air breath analysis to identify specific chemical species, compare their sensibility, and predictive value associated, and not with the CT scan.
Evaluate the follow up to the french guidelinesFollow up after the 1 year visitRatio between the participant at the cohort and who have done the scanner 2 years post Year1 one, and the participant at the cohort.
Evaluate the participation rate at 1 year and identify the factors that trigger it.At 1Year follow-upRatio between the number of participants who underwent the Year 1 CT scan and the number of participants.

Countries

France

Contacts

Primary ContactSébastien COURAUD, Pr
sebastien.couraud@chu-lyon.fr04.78.86.44.01
Backup ContactJulie DE BERMONT
Julie.de-bermont@chu-lyon.fr+33 0478866698

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026